RE:RE:Capacity?I must agree with Cash: No. Part of the problem we all seem to have is being patient while anticipating a flow of positive news. I certainly have fallen victim to this, leading to my speculation about news, and I have only been wrong. As Eunice and others have said, you just can't speculate. We were spoiled by the incredibly positive news flow around the Christmas period. I had thought more news would come once the warrants were done, and the share price would have run much higher, but I was mistaken: the share price has suffered along with the general market malaise and the lack of concrete news. There are many questions, all with potentially very positive and market moving answers, but we just are not hearing anything. For example, as I have mentioned previously, I think, what is going on with EU approval and expansion in the huge European market? What IS the production capacity in Quebec and does the company have an idea of when this capacity will be reached? What are the plans to increase capacity in Quebec or elsewhere to meet demand, in 2017 and beyond, for example, (a great problem to have, I might add)? What do we make of reports, here, of increased hiring that some have speculated relates to adding a second shift in Quebec to meet growing demand? Getinge's Myers was extremely positive on TSO3 on their year end cc, calling it a "star" for them, but how is the relationship with Getinge evolving? What are the plans for an upgraded 80L smaller unit for the OR, especially given all the cash now on hand, some of which will presumably used for R&D? What did and does the order book look like in the first months of the deal with Getinge, and what sales and deliveries have been achieved? Is any forward guidance possible? What is the status of the FDA submissions and discussions, and when might we expect extended claims and claims about the Q180V be approved in the US, (though, of course, TSO3 might just be speculating themselves on this one, as FDA is not exactly predictable or transparent)? And, what of the simplest question: when will the year end be released and when will the cc be held? (Note that last year the cc for March 16 was not announced until just a week before on March 7. One week's notice is not usual or adequate, at least in my humble experience.) I do hope we won't be waiting until the cc to have some or all of these questions answered, but one never knows. I continue to believe TOS remains extremely undervalued with game changing and new standand of care technology. I hope that Rumble, and others, especially our new COO and CFO, can keep growing pains to a minimum and continue to unlock the considerable value, here. Thanks.